Clinical Trials in Phoenix

Showing 2121-2140 of 16,646 trials

Safety and Immunogenicity of NVX-CoV2705

NCT07079670

This study is a Phase 3 trial designed to check the safety and immune response to a new Omicron JN.1 COVID-19 vaccine. Study researchers will give a single dose of this vaccine, called NVX-CoV2705, to approximately 120 participants. This includes adults aged 65 and older, and individuals aged 12 to 64 who have existing health conditions that put them at high risk for severe COVID-19. All participants must have received a previous COVID-19 vaccine at least 90 days before joining this study. Study researchers will be closely monitoring participants for their immune response for 28 days and collecting safety data for 180 days after vaccination.

COVID-19SARS-CoV-2 Infection

Sanofi676 participantsStarted Oct 2025

Phoenix, Arizona, United States • Melrose Park, Illinois, United States • Lenexa, Kansas, United States +7 more locations

Active Not RecruitingPhase 3< 1 mile

A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

NCT06502366

The purpose of this study is to assess the PD equivalence of the approved asthma combination therapy, BDA, delivered using the proposed replacement propellant HFO compared with BDA delivered using the currently approved propellant HFA in participants with asthma.

Asthma

AstraZeneca422 participantsStarted Jul 2024

Mobile, Alabama, United States • Sheffield, Alabama, United States • Phoenix, Arizona, United States +125 more locations

Safety and Immunogenicity of NVX-CoV2705

A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

Find Trials by Condition in Phoenix

A Study of AMDX-2011P in Participants With Alzheimer's Disease

Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment

A Study of AMDX-2011P in Participants With CAA

REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Safety and Efficacy of the VERTICA® RF Device for the Treatment of ED

A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing

A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)

A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

Study of Bitopertin in Participants With EPP or XLP (APOLLO)

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder Surgery

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)